Cxbladder Commercial Evaluation by Johns Hopkins Medicine

15 October 2018
Company Announcement

CXBLADDER COMMERCIAL EVALUATION BY JOHNS HOPKINS MEDICINE

Cancer diagnostics company, Pacific Edge, advises that Johns Hopkins Medicine has commenced their commercial
evaluation of Cxbladder, the company’s non-invasive molecular diagnostic test for the detection and management
of bladder cancer, with a number of urologists at the institution.

Johns Hopkins Medicine in the USA is an $8 billion integrated global health enterprise and one of the leading health
care systems in the United States. It operates six academic and community hospitals (including Johns Hopkins
Hospital which has been consistently ranked among the top hospitals in the US by U.S. News & World Report for 29
years), four suburban health care and surgery centres, and 39 primary and specialty care outpatient sites. With
over 40,000 employees, it is one of the largest private employers in the state of Maryland in the USA.

An initial select group of Johns Hopkins urologists will use Cxbladder for patients under surveillance for the
recurrence of bladder cancer. The commercial evaluation will allow John Hopkins’ urologists to evaluate and
determine the best fit for Cxbladder within their clinical practice and provide data specific to their organization and
patients.

CEO of Pacific Edge, David Darling, said: “This is a significant step forward having Cxbladder considered for use by
one of the most prestigious medical organisations in the world. It is extremely difficult for small companies with
new technologies to gain the attention of the leading physicians and access to organisations such as Johns Hopkins
Medicine and this commercial evaluation is a major accomplishment for our company.”

CEO of Pacific Edge Diagnostics USA, Jackie Walker, said: “We are also in discussions with a number of other large,
institutional healthcare organizations in the USA with a goal to make Cxbladder broadly available to their patients
across the US.”

ENDS

For more information contact:

David Darling
Chief Executive Officer
Pacific Edge Ltd
P: +64 (3) 479 5800

OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com
Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and
commercialisation of diagnostic and prognostic tests for better detection and management of cancer. Its Cxbladder suite of
non-invasive, simple to use and accurate diagnostic tests provide actionable results, and better detection and management of
urothelial cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through
its wholly owned central laboratories in New Zealand and the USA. The company’s products have been tested and validated in
international multi-centre clinical studies.

ABOUT Cxbladder Triage www.cxbladder.com
Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to
accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more
extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of patients
with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients who have a low
probability of having urothelial carcinoma.

15 October 2018
Company Announcement
ABOUT Cxbladder Detect www.cxbladder.com
Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of a
patients’ urine. Cxbladder Detect provides clinicians with a quick, cost effective and accurate measure of the presence of the
cancer as an effective adjunct to cystoscopy.

ABOUT Cxbladder Monitor www.cxbladder.com
Cxbladder Monitor allows urologists to monitor bladder cancer patients for recurrence of the disease. Bladder cancer has a
recurrence rate of 50-80% and requires life-long surveillance. Cxbladder Monitor accurately identifies patients with a prior
history of urothelial cancer (UC) whose Cxbladder Monitor score shows that they have a low probability of recurrent urothelial
carcinoma. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in the management of patients
for ongoing evaluation of recurrent bladder cancer.

ABOUT Cxbladder Resolve www.cxbladder.com
Cxbladder Resolve identifies those patients who are likely to have aggressive or more advanced bladder cancer. Cxbladder
Resolve, when used as part of the primary evaluation of haematuria and/or in conjunction with other Cxbladder tests (Triage,
Detect), is designed to assist clinicians by accurately identifying patients with a high probability of having high grade or late
stage bladder cancer, for whom alternative or expedited treatment options may be warranted, or who can be prioritised for
further investigation in high throughput settings.

Refer to www.cxbladder.com for more information.